Fluorouracil plus leucovorin induces submandibular salivary gland enlargement in rats.
The administration of 5-fluorouracil (FU) and leucovorin (LV) to rats induced a previously unreported sialoadenitis-like toxicity. Four different treatment regimens were used: daily-times-5 iv or ip injections of LV (200 mg/kg) followed 30 minutes later by FU (27.5 mg/kg or 35 mg/kg). These treatments resulted in 3 severity levels of systemic toxicity indicated by changes in body weight. In addition to the well known FU+LV-induced diarrhea, myelosuppression, and stomatitis, facial edema, and enlargement of the submandibular salivary gland were consistently seen. Facial edema occurred almost exclusively in rats that subsequently underwent excessive weight loss and were euthanized. The submandibular, but not parotid or sublingual, salivary gland was enlarged and the severity of this effect changed in a bell-shaped relationship with respect to increasing FU+LV induced loss of body weight. Histologic examination of affected glands established the occurrence of bacterial infection, sialoadenitis and destruction of gland tissue. This paper provides the first known documentation of FU+LV treatment-induced selective pathology of the submandibular salivary gland. The selectivity of this toxicity, apparently not normally seen in humans, to the submandibular salivary gland of the rat is of interest and its mechanism warrants further investigation.
Ewens
Andrew D
AD
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
Mihich
Enrico
E
Ehrke
M Jane
MJ
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D001854:Bone Marrow Cells / Q000187:drug effects / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D041905:Erythroid Cells / Q000187:drug effects / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000633:toxicity*; D006400:Hematocrit; D006454:Hemoglobins; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D002955:Leucovorin / Q000633:toxicity*; D007962:Leukocytes / Q000187:drug effects / Q000473:pathology; D051381:Rats; D011916:Rats, Inbred F344; D013363:Submandibular Gland / Q000187:drug effects* / Q000473:pathology
D000964:Antimetabolites, Antineoplastic; D006454:Hemoglobins; D002955:Leucovorin; D005472:Fluorouracil